# Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT00538824** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 5 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** thalidomide
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00538824
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2010-09-22
- **Final completion:** 2010-09-22
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2018-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538824, "Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00538824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*